OGNNYSEPharmaceutical PreparationsFiscal year ends December 31
Organon & Co.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$13.75−0.01 (-0.07%)
Close on Oct 19, 2026
- Market cap
- $3.72B
- P/E (TTM)
- 17.6
- Dividend yield
- 2.47%
Organon & Co. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexplanon/Implanon NXT | $230.00M | $201.00M | $210.00M | $223.00M | $240.00M | $248.00M | $259.00M | $243.00M | $242.00M | $220.00M | $231.00M | $220.00M | 14.8% | -4.2% |
| Other | $96.00M | $87.00M | $85.00M | $88.00M | $87.00M | $78.00M | $87.00M | $84.00M | $72.00M | $84.00M | $79.00M | $76.00M | 6.2% | +10.3% |
| Zetia | $96.00M | $87.00M | $90.00M | $93.00M | $74.00M | $85.00M | $77.00M | $81.00M | $75.00M | $84.00M | $69.00M | $69.00M | 6.2% | +29.7% |
| Atozet | $80.00M | $85.00M | $67.00M | $95.00M | $86.00M | $77.00M | $77.00M | $125.00M | $140.00M | $132.00M | $122.00M | $126.00M | 5.1% | -7.0% |
| Other Non-Opiod Pain, Bone and Dermatology | $79.00M | $68.00M | $72.00M | $80.00M | $80.00M | $68.00M | $68.00M | $74.00M | $78.00M | $72.00M | $68.00M | $74.00M | 5.1% | -1.2% |
| Hadlima | $79.00M | $67.00M | $69.00M | $63.00M | $50.00M | $47.00M | $44.00M | $40.00M | $28.00M | $30.00M | $24.00M | $8.00M | 5.1% | +58.0% |
| Arcoxia | $69.00M | $59.00M | $70.00M | $71.00M | $63.00M | $62.00M | $59.00M | $69.00M | $68.00M | $75.00M | $50.00M | $64.00M | 4.4% | +9.5% |
| Renflexis | $65.00M | $57.00M | $61.00M | $70.00M | $63.00M | $57.00M | $64.00M | $72.00M | $69.00M | $69.00M | $77.00M | $69.00M | 4.2% | +3.2% |
| Follistim AQ | $59.00M | $61.00M | $58.00M | $64.00M | $74.00M | $69.00M | $66.00M | $63.00M | $62.00M | $46.00M | $83.00M | $54.00M | 3.8% | -20.3% |
| Nasonex | $58.00M | $65.00M | $65.00M | $60.00M | $66.00M | $72.00M | $76.00M | $63.00M | $60.00M | $77.00M | $69.00M | $60.00M | 3.7% | -12.1% |
| Emgality | $54.00M | $54.00M | $49.00M | $51.00M | $42.00M | $32.00M | $38.00M | $29.00M | $30.00M | $10.00M | $0 | $0 | 3.5% | +28.6% |
| Cozaar/Hyzaar | $50.00M | $57.00M | $53.00M | $55.00M | $56.00M | $55.00M | $57.00M | $59.00M | $60.00M | $67.00M | $56.00M | $68.00M | 3.2% | -10.7% |
| Singulair | $48.00M | $40.00M | $59.00M | $53.00M | $66.00M | $74.00M | $84.00M | $85.00M | $93.00M | $98.00M | $114.00M | $91.00M | 3.1% | -27.3% |
| Other Women's Health | $45.00M | $46.00M | $46.00M | $43.00M | $42.00M | $43.00M | $39.00M | $40.00M | $34.00M | $43.00M | $41.00M | $33.00M | 2.9% | +7.1% |
| Diprospan | $44.00M | $35.00M | $38.00M | $41.00M | $41.00M | $30.00M | $37.00M | $37.00M | $37.00M | $29.00M | $33.00M | $31.00M | 2.8% | +7.3% |
| Dulera | $41.00M | $35.00M | $35.00M | $34.00M | $41.00M | $43.00M | $52.00M | $48.00M | $47.00M | $56.00M | $50.00M | $49.00M | 2.6% | 0.0% |
| Propecia | $36.00M | $30.00M | $28.00M | $33.00M | $32.00M | $26.00M | $32.00M | $28.00M | $28.00M | $23.00M | $33.00M | $22.00M | 2.3% | +12.5% |
| Vtama | $35.00M | $25.00M | $39.00M | $34.00M | $31.00M | $24.00M | $12.00M | $0 | $0 | $0 | – | – | 2.2% | +12.9% |
| Marvelon/Mercilon | $32.00M | $26.00M | $24.00M | $31.00M | $33.00M | $39.00M | $31.00M | $29.00M | $41.00M | $33.00M | $37.00M | $30.00M | 2.1% | -3.0% |
| Clarinex | $30.00M | $31.00M | $30.00M | $25.00M | $34.00M | $34.00M | $27.00M | $27.00M | $35.00M | $37.00M | $29.00M | $28.00M | 1.9% | -11.8% |
| Nuva Ring | $27.00M | $24.00M | $16.00M | $26.00M | $28.00M | $22.00M | $25.00M | $23.00M | $29.00M | $38.00M | $39.00M | $43.00M | 1.7% | -3.6% |
| Ganirelix Acetate Injection | $26.00M | $26.00M | $24.00M | $22.00M | $27.00M | $27.00M | $27.00M | $26.00M | $27.00M | $29.00M | $22.00M | $25.00M | 1.7% | -3.7% |
| Fosamax | $25.00M | $29.00M | $36.00M | $40.00M | $34.00M | $33.00M | $39.00M | $38.00M | $35.00M | $40.00M | $36.00M | $41.00M | 1.6% | -26.5% |
| Other Cardiovascular | $25.00M | $28.00M | $28.00M | $33.00M | $34.00M | $30.00M | $34.00M | $29.00M | $32.00M | $38.00M | $27.00M | $41.00M | 1.6% | -26.5% |
| Vytorin | $21.00M | $21.00M | $25.00M | $25.00M | $27.00M | $23.00M | $26.00M | $26.00M | $28.00M | $28.00M | $29.00M | $33.00M | 1.3% | -22.2% |
| Proscar | $20.00M | $26.00M | $24.00M | $27.00M | $22.00M | $24.00M | $22.00M | $23.00M | $23.00M | $26.00M | $20.00M | $25.00M | 1.3% | -9.1% |
| Bildyos/Bilprevda | $19.00M | – | – | – | $0 | – | – | – | – | – | – | – | 1.2% | – |
| Other Respiratory | $18.00M | $12.00M | $12.00M | $12.00M | $14.00M | $13.00M | $18.00M | $14.00M | $13.00M | $9.00M | $12.00M | $20.00M | 1.2% | +28.6% |
| Brenzys | $14.00M | $20.00M | $21.00M | $23.00M | $22.00M | $14.00M | $14.00M | $27.00M | $12.00M | $24.00M | $28.00M | $13.00M | 0.9% | -36.4% |
| Other | $14.00M | $18.00M | $15.00M | $21.00M | $23.00M | $22.00M | $30.00M | $26.00M | $31.00M | $29.00M | $19.00M | $24.00M | 0.9% | -39.1% |
| Other Biosimilars | $12.00M | $24.00M | $11.00M | $9.00M | $7.00M | $5.00M | $6.00M | $7.00M | – | – | – | – | 0.8% | +71.4% |
| Ontruzant | $6.00M | $5.00M | $19.00M | $31.00M | $31.00M | $18.00M | $34.00M | $20.00M | $48.00M | $39.00M | $62.00M | $40.00M | 0.4% | -80.6% |
| Rosuzet | $5.00M | $6.00M | $8.00M | $6.00M | $6.00M | $4.00M | $13.00M | $11.00M | $9.00M | $16.00M | $18.00M | $17.00M | 0.3% | -16.7% |
| Jada | $0 | $5.00M | $20.00M | $20.00M | $18.00M | $15.00M | $18.00M | $16.00M | $14.00M | $13.00M | $12.00M | $13.00M | 0.0% | -100.0% |
| Aybintio | – | – | – | – | $4.00M | $5.00M | $6.00M | $7.00M | $7.00M | $8.00M | $9.00M | $12.00M | – | – |
| Tofidence | – | – | – | – | $3.00M | – | – | – | $0 | – | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intl | $1.16B | $1.10B | $1.14B | $1.20B | $1.18B | $1.10B | $1.18B | $1.18B | $1.22B | $1.25B | $1.19B | $1.15B | 74.5% | -1.7% |
| Europe and Canada | $432.00M | $412.00M | $406.00M | $417.00M | $419.00M | $376.00M | $420.00M | $436.00M | $457.00M | $450.00M | $414.00M | $392.00M | 27.7% | +3.1% |
| United States | $398.00M | $358.00M | $372.00M | $406.00M | $414.00M | $412.00M | $416.00M | $398.00M | $388.00M | $371.00M | $411.00M | $370.00M | 25.5% | -3.9% |
| Latin America, Middle East, Russia, and Africa | $269.00M | $247.00M | $262.00M | $286.00M | $285.00M | $240.00M | $266.00M | $243.00M | $251.00M | $274.00M | $278.00M | $239.00M | 17.3% | -5.6% |
| Asia Pacific and Japan | $232.00M | $226.00M | $248.00M | $251.00M | $250.00M | $251.00M | $244.00M | $260.00M | $260.00M | $287.00M | $260.00M | $284.00M | 14.9% | -7.2% |
| China | $208.00M | $194.00M | $202.00M | $219.00M | $204.00M | $204.00M | $213.00M | $212.00M | $216.00M | $206.00M | $203.00M | $202.00M | 13.4% | +2.0% |
| Other | $19.00M | $23.00M | $17.00M | $23.00M | $22.00M | $30.00M | $33.00M | $33.00M | $35.00M | $34.00M | $32.00M | $32.00M | 1.2% | -13.6% |
From the segment and revenue-disaggregation notes of Organon's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.